Hospital General, Universidad de Valencia, Valencia, Spain; CIBER Fisiopatología Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, Madrid, Spain.
CIBER Fisiopatología Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, Madrid, Spain; Servicio de Psiquiatría, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain; Departamento de Ciencias Clínicas, Facultad de Medicina, Universidad de Barcelona, Barcelona, Spain.
An Pediatr (Engl Ed). 2021 Jun;94(6):421.e1-421.e4. doi: 10.1016/j.anpede.2021.01.003. Epub 2021 Mar 10.
High blood pressure is a clearly established modifiable risk factor for cardiovascular and renal disease. Although most of its adverse effects develop in adulthood, it has become clear that high BP is a lifelong problem that can manifest early in life. While few would dispute the importance of taking effective steps to identify and manage this condition in middle-aged and elderly individuals, relatively little attention has been paid to the problem of high BP in children and adolescents. Therefore, the development of actions focused on early childhood, childhood and adolescence and the investigation of the underlying causes of this epidemic are of utmost importance. There is a pressing need for comprehensive pan-European action to increase the knowledge on the prevention, diagnosis and treatment of high blood pressure in children and adolescents, the current scarcity of which impedes the development of consensus across different research fields and hinders efforts to introduce changes in clinical practice. There are some aspects that demand urgent action: the definition of hypertension, the prevalence of high BP in Europe, accurate measurement for early identification, the assessment of hypertension-mediated organ damage and the development and implementation of prevention strategies. In order to provide answers to all of these unanswered questions and challenges, a multidisciplinary network was established, maintained and funded by the European Cooperation in Science and Technology (COST) Association. COST is a funding organization for the creation of research networks known as COST Actions. In this case, the network will promote coordinated and collaborative activities on personalized preventive measures for children and adolescents across Europe.
高血压是明确的可改变的心血管和肾脏疾病的危险因素。虽然它的大多数不良影响发生在成年期，但很明显，高血压是一个终身问题，可以在生命早期表现出来。虽然很少有人会质疑采取有效措施来识别和管理中年和老年人的这种情况的重要性，但相对较少关注儿童和青少年的高血压问题。因此，制定针对幼儿、儿童和青少年的行动并调查这种流行病的根本原因非常重要。非常需要在整个欧洲采取全面行动，以增加对儿童和青少年高血压预防、诊断和治疗的了解，目前这方面的知识匮乏，阻碍了不同研究领域达成共识，并阻碍了在临床实践中引入变革的努力。有一些方面需要紧急行动：高血压的定义、欧洲高血压的流行情况、早期识别的准确测量、高血压介导的器官损伤评估以及预防策略的制定和实施。为了回答所有这些未解决的问题和挑战，一个由欧洲科学技术合作组织（COST）协会建立、维护和资助的多学科网络成立了。COST 是一个为创建称为 COST 行动的研究网络提供资金的组织。在这种情况下，该网络将促进欧洲针对儿童和青少年的个性化预防措施的协调和协作活动。
